• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc. (Amendment)

    2/14/24 8:52:31 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email
    SC 13G/A 1 tm246235d9_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    KalVista Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common stock, $0.001 par value

    (Title of Class of Securities)

     

    483497103

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 483497103        Page 2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page  3 of 14

     

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page 4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page 5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page 6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page 7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨ 

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page 8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)    (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,824,731 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,824,731 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,824,731 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    14.0% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

     

     

     

    CUSIP No. 483497103        Page 9 of 14

     

    Introductory Note:  This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of KalVista Pharmaceuticals, Inc.
     
    Item 1.
     
      (a)

    Name of Issuer

     

    KalVista Pharmaceuticals, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    55 Cambridge Parkway, Suite 901E

    Cambridge, MA 02142

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence
         
        New York Office: Palo Alto Office:
           
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018  

     

      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.001 par value

     
      (e)

    CUSIP Number

     

    483497103

     

     

     

     

    CUSIP No. 483497103        Page  10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
     
    Item 4. Ownership
       
      (a) Amount beneficially owned as of February 8, 2024:

      

    Venrock Healthcare Capital Partners III, L.P.    4,824,731 (1) 
    VHCP Co-Investment Holdings III, LLC    4,824,731 (1) 
    Venrock Healthcare Capital Partners EG, L.P.    4,824,731 (1) 
    VHCP Management III, LLC    4,824,731 (1) 
    VHCP Management EG, LLC    4,824,731 (1) 
    Nimish Shah    4,824,731 (1) 
    Bong Koh    4,824,731 (1) 

      

    (b) Percent of class as of February 8, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.    14.0% (2) 
    VHCP Co-Investment Holdings III, LLC    14.0% (2) 
    Venrock Healthcare Capital Partners EG, L.P.    14.0% (2) 
    VHCP Management III, LLC    14.0% (2) 
    VHCP Management EG, LLC    14.0% (2) 
    Nimish Shah    14.0% (2) 
    Bong Koh    14.0% (2) 

     

      (c) Number of shares as to which the person has as of February 8, 2024:
         
        (i)       Sole power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

      

        (ii) Shared power to vote or to direct the vote:

      

    Venrock Healthcare Capital Partners III, L.P.    4,824,731 (1) 
    VHCP Co-Investment Holdings III, LLC    4,824,731 (1) 
    Venrock Healthcare Capital Partners EG, L.P.    4,824,731 (1) 
    VHCP Management III, LLC    4,824,731 (1) 
    VHCP Management EG, LLC    4,824,731 (1) 
    Nimish Shah    4,824,731 (1) 
    Bong Koh    4,824,731 (1) 

     

     

     

     

     

     

    CUSIP No. 483497103        Page 11 of 14

     

        (iii)       Sole power to dispose or to direct the disposition of:

      

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

        (iv)       Shared power to dispose or to direct the disposition of:

      

    Venrock Healthcare Capital Partners III, L.P.    4,824,731 (1) 
    VHCP Co-Investment Holdings III, LLC    4,824,731 (1) 
    Venrock Healthcare Capital Partners EG, L.P.    4,824,731 (1) 
    VHCP Management III, LLC    4,824,731 (1) 
    VHCP Management EG, LLC    4,824,731 (1) 
    Nimish Shah    4,824,731 (1) 
    Bong Koh    4,824,731 (1) 

      

    (1)Consists of (i) 1,059,054 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 105,940 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,659,737 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon 34,558,709 shares of Common Stock outstanding as of November 30, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on December 7, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

     

     

     

    CUSIP No. 483497103        Page  12 of 14

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
       

     

     

     

     

    CUSIP No. 483497103        Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
             
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    VHCP Co-Investment Holdings III, LLC      
             
    By: VHCP Management III, LLC      
    Its: Manager      
             
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther      
      Its: Authorized Signatory      
             
    VHCP Management III, LLC   VHCP Management EG, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    Nimish Shah      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      
             
    Bong Koh      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      

      

     

     

     

    CUSIP No. 483497103        Page 14 of 14

     

    EXHIBITS

      

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G/A filed on December 28, 2023)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G/A filed December 28, 2023)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G/A filed on December 28, 2023)

     

     

     

    Get the next $KALV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/9/2026$32.00 → $35.00Buy
    Needham
    1/6/2026$28.00 → $32.00Buy
    Needham
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

    1/31/25 7:03:28 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026. The following poster presentations will take place on Friday, February 27 from 2:45–3:45 pm ET in the Convention Center, Level 2, Hall E: Response Drivers in Sebetralstat Placebo-controlled Clinical Trials: Jonathan Bernstein, Emel Aygören-Pürsün, Danny Cohn, Henriette Farkas, William Lumry, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Paul Audhya, Erik Hansen, Nathan Teuscher, Marc Riedl. On-demand

    2/12/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each cas

    2/3/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

    Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively 1,318 patient start forms received in the US through December, reflecting continued rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE); Germany launch also demonstrating strong early adoption Partnered with Multicare Pharma to commercialize sebetralstat in Latin America; third commercial partnership in 10 months KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and

    1/8/26 4:05:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operations Officer Arif Bilal

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    1/21/26 4:11:45 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Sweeny Nicole

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    1/21/26 4:11:12 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Piekos Brian

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    1/21/26 4:10:39 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    SEC Filings

    View All

    SEC Form S-8 filed by KalVista Pharmaceuticals Inc.

    S-8 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    1/26/26 5:00:38 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    1/8/26 4:47:09 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by KalVista Pharmaceuticals Inc.

    SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    12/30/25 4:28:56 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/11/25 7:51:08 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    View All

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti

    10/2/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 12:02:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered

    11/3/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

    -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome

    9/11/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care